CORDIS · 848011 · H2020
DC-ren Drug combinations for rewriting trajectories of renal pathologies in type II diabetes (DC-ren)
Coordinator: MEDIZINISCHE UNIVERSITAT INNSBRUCK (AT)
Diabetic Kidney Disease (DKD) is highly prevalent in type 2 diabetes, with major impact on patients and healthcare systems. The complex disorder, further modulated by cardiovascular comorbidities, presents as an accumulation of risk factors, which we treat with drug combinations. While the overall benefit of this approach is evident on a cohort level, individual patients show remarkable heterogeneity in drug response, and lack of guidance on personalized medication results in suboptimal control of the disorder.For resolving variability, we propose a new concept for personalization of drug com…
About Horizon 2020 (2014–2020)
Horizon 2020 was the EU's flagship research and innovation programme for 2014–2020, with a budget of around €77 billion. It bundled FP7's strands with the EIT and the Competitiveness and Innovation Programme, introduced a stronger societal-challenge orientation, and pushed the funding logic toward closer-to-market innovation. New calls closed in 2020 but funded projects continued through 2024.
EU contribution: €6.0M awarded to the consortium. The project runs over approximately 5 years from 2020-01-01 to 2024-12-31.
Full record on CORDIS — partners, deliverables, publications, news.
Open on cordis.europa.eu → Grant DOI ↗More from AT
see all →- EMPOWER — Eco-operated, Modular, highly efficient, and flexible multi-POWERtrain for long-haul heavy-duty vehicles101096028 · HORIZON · €18.0M
- M-ERA.NET3 — ERA-NET for research and innovation on materials and battery technologies, supporting the European Green Deal.958174 · H2020 · €15.0M
- iPC — individualizedPaediatricCure: Cloud-based virtual-patient models for precision paediatric oncology826121 · H2020 · €14.7M
- MORE-TEM — MOmentum and position REsolved mapping Transmission Electron energy loss Microscope951215 · H2020 · €14.0M
- PoCCardio — Personalised Medicine by using an Advanced Point-of-Care Tool for Stratified Treatment in High Risk Cardiovascular Patients (PoCCardio)101095432 · HORIZON · €14.0M
- ThoriumNuclearClock — Thorium nuclear clocks for fundamental tests of physics856415 · H2020 · €13.8M
Other H2020 projects
see all →- EUROfusion — Implementation of activities described in the Roadmap to Fusion during Horizon 2020 through a Joint programme of the members of the EUROfusion consortium633053 · DE · €678.8M
- H2020 — COST at a turning point: A unique framework for pan-European ST cooperation as clear demonstration of European values681463 · BE · €178.2M
- HBP SGA3 — Human Brain Project Specific Grant Agreement 3945539 · BE · €150.0M
- COVID-19 VACCINES — PROPOSAL FOR FUNDING RESEARCH DEVELOPMENT AND MANUFACTURING OF VACCINE AGAINST COVID-19101018100 · NO · €100.0M
- UNITE4TB — ACADEMIA AND INDUSTRY UNITED INNOVATION AND TREATMENT FOR TUBERCULOSIS101007873 · NL · €92.5M
- ERA4TB — EUROPEAN REGIMEN ACCELERATOR FOR TUBERCULOSIS853989 · ES · €89.8M
Frequently asked questions
- Who funds this research project?
- This project is funded by the European Union through the Horizon 2020 (2014–2020) programme, under the RIA funding scheme.
- What is the EU contribution?
- The European Commission contributes €6.0M toward a total project budget of €6.0M.
- Which EU programme funds it?
- The project is funded under Horizon 2020 (2014–2020), call H2020-SC1-BHC-2018-2020.
- Who coordinates the project?
- The project is coordinated by MEDIZINISCHE UNIVERSITAT INNSBRUCK (AT).
- What is the project timeline?
- The project runs from 2020-01-01 to 2024-12-31 — approximately 5 years.
- Where can I find the full project record?
- The complete record — partners, deliverables, publications and news — is published on CORDIS under project ID 848011.